Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial

This publication has 29 references indexed in Scilit:

• Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial
  EBioMedicine, 2022
• AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder
  Multiple Sclerosis and Related Disorders, 2022
• Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum Study
  Multiple Sclerosis and Related Disorders, 2022
• Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy
  Multiple Sclerosis and Related Disorders, 2021
• New Therapeutic Landscape in Neuromyelitis Optica
  Current Treatment Options in Neurology, 2021
• Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker
  Annals of Neurology, 2021
• Progressive patterns of neurological disability in multiple sclerosis and neuromyelitis optica spectrum disorders
  Scientific Reports, 2020
• Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial
  The Lancet Neurology, 2020
• Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
  The Lancet, 2019
• Intrathecal pathogenic anti–aquaporin‐4 antibodies in early neuromyelitis optica
  Annals of Neurology, 2009